| Sep 5 |
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
|
| Sep 4 |
High Growth Tech Stocks To Watch In The United States
|
| Aug 30 |
Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory
|
| Aug 28 |
Aldeyra Therapeutics Has Data To Trigger AbbVie Partnership
|
| Aug 9 |
Aldeyra’s Phase III clinical trial of Reproxalap meets primary endpoint
|
| Aug 8 |
Aldeyra climbs after late-stage success for dry eye disease therapy
|
| Aug 8 |
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap
|
| Aug 7 |
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap
|
| Jul 31 |
Owning 36% shares,institutional owners seem interested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX),
|
| Jun 20 |
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
|
